Franklin Resources Inc. Takes Position in Astrana Health, Inc. (NASDAQ:ASTH)

Franklin Resources Inc. purchased a new position in Astrana Health, Inc. (NASDAQ:ASTH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 19,908 shares of the company’s stock, valued at approximately $1,187,000.

Several other institutional investors also recently added to or reduced their stakes in ASTH. GAMMA Investing LLC bought a new stake in Astrana Health in the third quarter worth about $34,000. Nisa Investment Advisors LLC bought a new stake in shares of Astrana Health in the 3rd quarter worth approximately $35,000. KBC Group NV purchased a new position in Astrana Health in the third quarter valued at approximately $70,000. Quarry LP bought a new stake in shares of Astrana Health in the third quarter valued at $77,000. Finally, Quest Partners LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at $133,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Shares of ASTH opened at $32.72 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average price of $44.45 and a 200-day moving average price of $47.57. The company has a market cap of $1.84 billion, a PE ratio of 25.17, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13. Astrana Health, Inc. has a 12-month low of $32.21 and a 12-month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same quarter in the prior year, the firm earned $0.47 EPS. As a group, equities analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ASTH. Robert W. Baird lifted their target price on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. BTIG Research raised their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen began coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective on the stock. KeyCorp began coverage on Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Astrana Health has an average rating of “Moderate Buy” and an average target price of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.